GABA and Glutamate Transporters in Brain by Yun Zhou & Niels Christian Danbolt
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 11 November 2013
doi: 10.3389/fendo.2013.00165
GABA and glutamate transporters in brain
Yun Zhou and Niels Christian Danbolt*
The Neurotransporter Group, Department of Anatomy, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
Edited by:
Leif Hertz, China Medical University,
China
Reviewed by:
Leif Hertz, China Medical University,
China
Fiorenzo Conti, Università Politecnica
delle Marche, Italy
*Correspondence:
Niels Christian Danbolt , The
Neurotransporter Group, Department
of Anatomy, Institute of Basic Medical
Sciences, University of Oslo, P.O. Box
1105 Blindern, Oslo N-0317, Norway
e-mail: n.c.danbolt@medisin.uio.no
The mammalian genome contains four genes encoding GABA transporters (GAT1, slc6a1;
GAT2, slc6a13; GAT3, slc6a11; BGT1, slc6a12) and five glutamate transporter genes
(EAAT1, slc1a3; EAAT2, slc1a2; EAAT3, slc1a1; EAAT4, slc1a6; EAAT5, slc1a7). These
transporters keep the extracellular levels of GABA and excitatory amino acids low and
provide amino acids for metabolic purposes. The various transporters have different prop-
erties both with respect to their transport functions and with respect to their ability to
act as ion channels. Further, they are differentially regulated. To understand the physiolog-
ical roles of the individual transporter subtypes, it is necessary to obtain information on
their distributions and expression levels. Quantitative data are important as the functional
capacity is limited by the number of transporter molecules. The most important and most
abundant transporters for removal of transmitter glutamate in the brain are EAAT2 (GLT-1)
and EAAT1 (GLAST), while GAT1 and GAT3 are the major GABA transporters in the brain.
EAAT3 (EAAC1) does not appear to play a role in signal transduction, but plays other roles.
Due to their high uncoupled anion conductance, EAAT4 and EAAT5 seem to be acting
more like inhibitory glutamate receptors than as glutamate transporters. GAT2 and BGT1
are primarily expressed in the liver and kidney, but are also found in the leptomeninges,
while the levels in brain tissue proper are too low to have any impact on GABA removal,
at least in normal young adult mice. The present review will provide summary of what is
currently known and will also discuss some methodological pitfalls.
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GLUTAMATE AND GABA AS NEUROTRANSMITTERS
Gamma-aminobutyric acid (GABA) and glutamate are, respec-
tively, the major inhibitory and the major excitatory neurotrans-
mitters in the mammalian central nervous system (1–3), and are
thereby involved directly or indirectly in most aspects of normal
brain function including cognition, memory, and learning. They
are exocytosed from nerve terminals, and it is currently debated
whether they are also exocytosed from astrocytes [e.g., Ref. (4–
6)]. When interpreting data in the literature, it is important to
keep in mind that astrocytic preparations differ greatly depend-
ing on the source of the cells and the culturing conditions, and
cultured astrocytes may differ substantially from mature brain
astrocytes (5).
THE IMPORTANCE OF CELLULAR UPTAKE OF GABA AND
GLUTAMATE
Both GABA and glutamate exert their signaling roles by acting on
receptors located on the surface of the cells expressing them [e.g.,
Ref. (7–13)]. Therefore it is the transmitter concentration in the
surrounding extracellular fluid that determines the extent of recep-
tor stimulation. It is of critical importance that the extracellular
Abbreviations: BGT1, betaine-GABA transporter (slc6a12); DTT, dithiothreitol;
EAAC1, excitatory amino acid carrier (EAAT3; slc1a1); EAAT, excitatory amino
acid transporter; GAT1, GABA transporter 1 (slc6a1); GAT2, GABA transporter
2 (slc6a13); GAT3, GABA transporter 3 (slc6a11); GABA, gamma-aminobutyric
acid; GLAST, glutamate–aspartate transporter (EAAT1; slc1a3); GLT-1, glutamate
transporter 2 (EAAT2; slc1a2).
concentrations are kept low [e.g., Ref. (3, 14–16)]. This is required
for a high signal to noise (background) ratio in synaptic as well as
in extrasynaptic transmission.
Low extracellular levels can only be maintained by cellular
uptake because there is no extracellular metabolism of GABA and
glutamate [e.g., Ref. (17–24)].
For glutamate, there is another reason to keep the extracellular
levels low. Excessive activation of glutamate receptors is harmful,
and glutamate is thereby toxic in high concentrations [for review
and references, see Ref. (3)].
EARLY CHARACTERIZATION OF GABA AND GLUTAMATE
UPTAKE
It was soon realized that the mechanisms responsible for the uptake
of GABA and glutamate are independent of each other (21, 25, 26)
and that there is heterogeneity both within GABA uptake (27)
and glutamate uptake (28–33). Uptake activity of both GABA and
glutamate uptake was found to be present both in glial cells and
in neurons [for review, see Ref. (1, 24, 34)]. The uptake processes
are electrogenic and in the case of glutamate uptake it is driven
by the ion gradients of K+ and Na+ [for review, see Ref. (35)]
while the uptake of GABA is driven by the gradients of Na+ and
Cl− (35–39). The dependency of the transport process on the
electrochemical gradients across the plasma membranes further
implies that the uptake can reverse if the gradients are sufficiently
weakened. In fact, during cerebral ischemia massive amounts of
glutamate are released (40) and transporter reversal may be one
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of the mechanisms [e.g., Ref. (41–45)] albeit not the only one
(3). Further, the transporters can operate as exchangers. The lat-
ter phenomenon complicated early attempts to study binding of
glutamate to the uptake sites in membrane preparations (46–48),
and it took some time before it was realized that transportable
uptake inhibitors induce release of internal endogenous substrates
by enabling heteroexchange [e.g., Ref. (3, 49)].
IDENTIFICATION OF GABA AND GLUTAMATE
TRANSPORTERS
The first neurotransmitter transporter to be molecularly identified
was the GABA transporter (Table 1) now known as GAT1 (slc6a1).
This was accomplished by purifying the protein in active form
using reconstitution of transport activity as the assay to monitor
the purification process (50). Based on peptide sequences derived
from the pure protein, probes were synthesized and cDNA was suc-
cessfully isolated from a rat brain library (51). This turned out to
be the first member of a new family of transporters. Another three
GABA transporters (GAT2, slc6a13; GAT3, slc6a11; BGT1, slc6a12)
were subsequently identified (52, 53). The first cloning of BGT1
resulted from screening of a Madin–Darby canine kidney (MDCK)
cell cDNA library for expression of a betaine transporter in Xeno-
pus oocytes (54). BGT1 homologs were subsequently cloned from
mouse brain (53), and from human brain (55) and kidney (56). In
fact, the mammalian genome contains about 20 transporters with
structural similarities to GAT1 (37, 38, 57). Interestingly, none of
these were glutamate transporters.
The first glutamate transporter (Table 2) to be isolated in
active form (58) and localized (59, 60) was the one now known
as EAAT2 [GLT-1; slc1a2; Ref. (61)]. Simultaneously, but inde-
pendently of each other, three other research teams succeeded in
cloning another two glutamate transporters using completely dif-
ferent approaches (62–64). The three human counterparts were
quickly identified and named Excitatory Amino Acid Transporter
(EAAT) 1–3 (65). Another two glutamate transporters were found
later: EAAT4 (66) and EAAT5 (67). All the EAATs catalyze Na+-
and K+-coupled transport of l-glutamate as well as l- and d-
aspartate, but not d-glutamate. Further, down-regulation of glial
glutamate transporters after glutamatergic denervation suggested
complex regulation (68). Glutamate transporter expression turned
out to be regulated via several different pathways and neurons were
found to influence astroglial expression levels [e.g., Ref. (69–72)].
In fact, there is regulation on apparently all levels from transcrip-
tion to posttranslational modification and trafficking (73, 74).
This degree of complexity suggested that the transporters might
have more roles than simply representing drainage and re-cycling
systems [for review, see Ref. (3, 73, 75–79)]. Pharmacological
manipulation of transporter expression or function would be
highly interesting from a therapeutic point of view (80). A spider
toxin has been found to enhance EAAT2 transport activity (81),but
the compound responsible has not yet been identified. Recently,
it was discovered EAAT2 expression can be increased by β-lactam
antibiotics (82,83),and that finding has got considerable attention.
FUNCTIONAL PROPERTIES OF GABA TRANSPORTERS
The molecular functioning of GAT1 has been extensively stud-
ied (84–92), but there are also data on the other three GABA
Table 1 | Overview of the nomenclature of plasma membrane GABA
transporters.
Name adopted by HUGO
(www.genenames.org)
Other names
GABA transporter 1 (GAT1;
slc6a1)
Rat GAT1, human GAT1, mouse GAT1
(51, 52)
GABA transporter 2 (GAT2;
slc6a13)
Rat GAT2, human GAT2, mouse GAT3
(52, 277)
GABA transporter 3 (GAT3;
slc6a11)
Rat GAT3, hGAT-3, mGAT4, GAT-B (52,
277, 278)
Betaine-GABA transporter
(BGT1; slc6a12)
Rat BGT1, rat GAT-4, rat NTBE, human
GAT-4, mouse GAT2 (52–56, 180)
Taurine transporter (TAUT; slc6a6) (279), (280)
Proton-coupled amino acid
transporter 1 (PAT1; slc36a1)
Imino acid carrier, LYAAT-1, tramdorin 3
(281)
The neurotransmitter transporter family (SLC6) comprises four GABA transporters
as well as the taurine transporter (280). Both the taurine transporter and the
proton-coupled amino acid transporter 1 (282) are able to transport GABA, but
with low affinity (Km >1 mM) and are therefore usually not classified as “GABA
transporters.”The nomenclature used here is the one adopted by the HUGO Gene
Nomenclature Committee (283).
Table 2 | Overview of the nomenclature of plasma membrane
glutamate transporters.
HUGO name Other names
Excitatory amino acid transporter 1 (EAAT1; slc1a3) GLAST (63–65)
Excitatory amino acid transporter 2 (EAAT2; slc1a2) GLT-1 (61, 65)
Excitatory amino acid transporter 3 (EAAT3; slc1a1) EAAC1 (62, 65, 211)
Excitatory amino acid transporter 4 (EAAT4; slc1a6) (66)
Excitatory amino acid transporter 5 (EAAT5; slc1a7) (67)
Glutamate transporters do not belong to the slc6-family, but to the slc1-family
(high-affinity glutamate and neutral amino acid transporter family). Although there
are several proteins with ability to transport glutamate, the term “glutamate
transporter” is usually used to describe the five “High-Affinity Glutamate Trans-
porters” also called “Excitatory Amino Acid Transporters (EAATs).” The actual
meanings of the acronyms (GLAST, glutamate–aspartate transporter; GLT-1, glu-
tamate transporter; EAAC, excitatory amino acid carrier; EAAT, excitatory amino
acid transporter) are not important, as they do not reflect functional differences
among the transporters. The nomenclature used here is the one adopted by the
HUGO Gene Nomenclature Committee (283).
transporters (93–100). GAT1 and GAT3 are coupled to both
sodium and chloride. Like for the glutamate transporters (see
below), there is also uncoupled transport (101–103). The affini-
ties for GABA vary greatly. The reported Km values for the
mouse isoforms are 0.8, 8, 18, and 80µM, respectively, for GAT3,
GAT1, GAT2, and BGT1 (52, 53, 104). Nipecotic acid and β-
guanidinopropionate inhibit the GAT1–3, but not the taurine
transporter (105). GAT2 (slc6a13) transports β-alanine and also
taurine with Km of 28 and 540µM, respectively (52, 106). Mouse
BGT1 (slc6a12) transports betaine with a Km of about 200µM,
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but no significant transport of β-alanine could be detected (53).
Mouse GAT2 and GAT3 are more potently inhibited by isoserine,
β-alanine, and hypotaurine than GAT1 and BGT1 (107). Tiagabine
is highly selective for GAT1 (24, 108, 109). Recently, new functional
assays have been developed for compound screening (110, 111)
leading to development of several new compounds (112–116).
FUNCTIONAL PROPERTIES OF GLUTAMATE TRANSPORTERS
Most of the reported Km values of EAAT2 for glutamate are at
around 20µM and the affinities of EAAT1 and EAAT3 differ from
EAAT2 with a factor of <2 (3), while the affinities of EAAT4 and
EAAT5 are, respectively, one order of magnitude higher and lower
(3,65–67). Stoichiometry of the transport mediated by EAAT1–3 is
exchange of one internal potassium ion with the following external
substrates: one glutamate, three sodium ions, and one hydrogen
ion (117–119). The coupling to three sodium ions makes these
transporters less prone to reversal than the GABA transporters
which are coupled to two sodium ions. In addition to the cou-
pled (stoichiometric) transport, there are uncoupled fluxes. Thus,
the transporters also function as chloride channels (66, 117, 120–
122). EAAT4 and EAAT5 have the largest chloride conductance,
and may function more as inhibitory glutamate receptors than as
transporters (123, 124). In addition, a general feature of sodium
coupled transport appears to be transport of water (125, 126).
Obviously, these transporters are complex molecules, and it is
important to determine their exact structure. Although the mam-
malian transporters have not yet been crystallized, a detailed pic-
ture is emerging (127, 128). The mammalian EAAT2 and EAAT3
proteins are believed to be homotrimers where the subunits are
non-covalently connected (129). This is supported by recent evi-
dence including crystallization of a bacterial glutamate transporter
(130, 131). However, crosslinking studies indicate that there may
be differences between the EAAT subtypes (123). These proteins
are integral membrane proteins and they depend on the lipid envi-
ronment. For instance, the GABA transporters, at least GAT1, need
cholesterol to be fully active (132). EAAT2 is more robust, but is
influenced by fatty acids such as arachidonic acid (133–135) and
oxidation (136, 137). Arachidonic acid elicits a substrate-gated
proton current associated with the glutamate transporter EAAT4
(138, 139).
All the five EAATs transport l-glutamate and dl-aspartate with
high affinities (3, 140). There are some important differences,
however. One of them is that EAAT3 transports cysteine (141).
Another is that EAAT2 is blocked by kainate and dihydrokainate
(65). Importantly, kainate analogs block both net uptake and
exchange [for the importance of this, see Figure 5 in Ref. (3)]
while most other inhibitors are substrates. Recently, a pan-EAAT
blocker was developed by Shimamoto and co-workers. They syn-
thesized a series of compounds (TBOA and variants) based on
aspartate (142). The only known biological effect of these com-
pounds is to bind to EAATs with higher affinity than glutamate
(143, 144) and they do not interact with ASCT2 (145). An EAAT1
selective inhibitor has also been developed (146).
LOCALIZATION AND FUNCTION – NUMBERS MATTER
Still, most of the data on protein distribution relies on immuno-
histochemistry. Unfortunately, validation of the specificity of
immunochemical labeling is difficult and the literature reflects that
[for detailed discussion, see Ref. (147–149)]. The most difficult
part is to obtain good negative controls. When studying human
samples, post-mortem proteolysis may complicate interpretation
because the termini of EAAT1 and EAAT2 are rapidly proteolyzed
(150–152). Post-mortem changes affect GAT3 more than GAT1
(153). It is a good idea to use additional methods, including in situ
hybridization and Western blotting. For instance, Western blotting
can be used to validate regional and temporal differences in label-
ing intensity. However, there are pitfalls here too. One of them is
that non-transporter proteins may interfere with the binding of
transporters to the blotting membranes causing underestimation
of expression levels (106, 154).
The presence of a protein is one thing. But to be physiologically
relevant, sufficient numbers of molecules must be present. The
number of molecules needed to accomplish a given task depends
on what that task is. This consideration is particularly relevant
for neurotransmitter transporters as the transport process is fairly
slow. The cycling time of EAAT2 and EAAT3 are about 30 gluta-
mate molecules per second at Vmax (14, 155, 156). EAAT5 is even
slower and is reported to behave as a slow-gated anion channel
with little glutamate transport activity being more than an order
of magnitude slower than EAAT2 (157). The cycling time for the
GABA transporters has not been determined, but is believed to be
similar to that of EAAT2.
The TBOA glutamate uptake blocker (143, 158) showed that
there is a rapid extracellular turnover of glutamate (159). Despite
that, the resting levels of extracellular glutamate in normal brains
are low, possibly as low as 25 nM (160) which is 0.1–0.2% of
the reported Km values for glutamate uptake (see above). At
this concentration <0.1% of the glutamate transporter mole-
cules are expected to be actively transporting. Consequently, if
ambient concentrations of 25 nM shall be maintained, then there
must be so many EAAT molecules that 0.1% of them is suffi-
cient to keep up with the release. In fact, this is what has been
determined experimentally (123, 155, 161, 162). Buffering synap-
tically released glutamate on a submillisecond time scale is just as
demanding (163).
Also the ambient GABA levels around synapses are low; prob-
ably well below 1µM (164–166) and thereby below the Km of
GAT3. The low levels mean that GABA is removed efficiently and
down to a level where BGT1 (and GAT2) is much less efficient
that GAT1 and GAT3. This illustrates the point that it is not inter-
esting whether a few BGT1 molecules can be found or not, but
whether there are enough of them to make a difference. Because
BGT1 has lower affinity (see above) and is expressed in the brain at
much lower levels than that GAT1, it cannot contribute to GABA
inactivation and does not affect seizure thresholds (167).
DISTRIBUTION OF GABA TRANSPORTERS
The purified rat GAT1 protein (50) was used to generate the first
antibodies to a GABA transporter and these were used to local-
ize GAT1 in young adult rat brain tissue (168). These antibodies
were probably selective for GAT1, but reactivity toward the other
GATs were never tested. Nevertheless this antibody did not label
cell bodies and the strongest labeling was found in GABAergic
terminals. Basket cell terminals around the base of the Purkinje
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FIGURE 1 | A schematic illustration of GABA and glutamate transporter
distributions around synapses in the hippocampus. Two glutamatergic
synapses (A,B) are shown forming synapses asymmetric specializations with
prominent post synaptic densities (PSD, one of which is labeled). GABAergic
synapses (C) are often onto dendritic trunks rather than spines, and the
synaptic specializations are typically symmetric. Three fine astrocyte branches
are indicated (g). Note that the synapses in the hippocampus are usually not
surrounded by astrocytes, but rather contacted by an astrocyte (like a finger
pointing to it, and typically from the postsynaptic side). Also note that there
are no astrocytes between synapse (A,B). About 1/3 of neighboring synapses
in the hippocampus have no astrocytes between them in contrast to the
molecular layer of the cerebellum where most synapses onto spines are
typically completely surrounded by astrocytes (Figure 2) and thereby isolated
from their neighbors (162, 275). Glutamate and GABA transporters are
indicated. EAAT1 (184, 185) and GAT3 (153, 172, 175–177) are selective for
astrocytes, while EAAT2 is predominantly expressed in astrocytes (59), but
there is also some (about 10%) in hippocampal nerve terminals (229). This has
some resemblance to GAT1 as GAT1 is mostly neuronal (170–173), but with
some expression in astrocytes; particularly in the thalamus (172). There is
more EAAT2 than EAAT1 in the hippocampus and the other way around in the
cerebellum (162, 184). EAAT3 is selective for neurons, but is expressed at
levels two orders of magnitude lower than EAAT2 and is targeted to dendrites
and cell bodies (193) (Copyright: Neurotransporter.org; Reproduced with
permission).
cells, for instance, were strongly labeled. Most GABAergic termi-
nals were labeled, but with two notable exceptions: striatonigral
and Purkinje cell axon terminals. There was also some labeling
of astrocytes. These findings were confirmed by antibodies pro-
duced to synthetic peptides (169, 170) and thereby to sequences
known to differ between GABA transporter subtypes (170–173).
In thalamus, however, GAT1 was not found in terminals. All the
immunolabeling was in astrocytes together with GAT3 (172).
GAT1 is present in neuronal cell bodies for a short time during
development (174). In contrast to GAT1, GAT3 (Figures 1–3) is
considered to be selectively expressed in astrocytes throughout the
CNS [e.g., Ref. (153, 172, 175–177)]. The highest GAT1 levels are
in the cerebral cortex while the highest GAT3 levels are in the
brainstem (178, 179).
In contrast, GAT2 and BGT1 are predominantly expressed in
hepatocytes in the liver and kidney (52, 53, 106, 180, 181). Within
the skull (Figure 4A),GAT2 is found only in the leptomeninges and
some large blood vessels (169, 181, 182) while BGT1 (Figure 4B)
is expressed in the leptomeninges (106, 178).
DISTRIBUTION OF GLUTAMATE TRANSPORTERS
When the first polyclonal and monoclonal antibodies were raised
against the purified EAAT2 protein (58), it was immediately clear
that EAAT2 is highly expressed in astrocytes in all parts of the brain
and spinal cord. The highest levels were found in the hippocampus
and the neocortex (59, 60). Soon thereafter antibodies were raised
to synthetic peptides representing parts of the various subtypes.
This made it easier to ensure that the antibodies were subtype
specific. The conclusions on the distribution of EAAT2 were con-
firmed (183, 184), while EAAT1 was localized for the first time
(184) and also this protein was found in astrocytes throughout the
central nervous system (184–188). With immunogold and elec-
tron microscopy, it was shown that both EAAT1 and EAAT2 are
preferentially targeted to the plasma membranes, and that plasma
membranes facing neuropil have higher densities than those fac-
ing cell bodies, other astrocytes, and pia mater (189). Quantitative
immunoblotting of brain tissue extracts compared with known
amounts of purified glutamate transporters showed that EAAT2
protein represents about 1% of the total forebrain protein and
that it is about four times more abundant than EAAT1 in the
hippocampus and six times less abundant than EAAT1 in the cere-
bellum (162). The high expression levels are part of the reason
why the first post-embedding immunogold electron micrographs
of EAAT1 and EAAT2 (189) as well as EAAT4 (123) were so clear.
Of course, good antibodies and good tissue preparation are key
factors, but to get good immunogold images, there must also be a
large number of molecules in the plane of the section.
Immunoadsorption of transport activity revealed that EAAT2
represent about 95% of the total glutamate uptake activity in
young adult forebrain tissue (59, 129). Deletion of the EAAT2 gene
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FIGURE 2 | A schematic illustration of glutamate transporter
distributions around parallel fiber synapses on Purkinje cell spines in
the molecular layer of the cerebellum. EAAT1 is expressed in the
astrocytes (Bergmann glial cells) at very high levels, and about six times
higher than EAAT2 (162, 184). Most of the EAAT4 protein is found in
cerebellar Purkinje cells (the glia-covered parts of the membranes of
Purkinje cell dendrites), but low levels are also found in scattered neurons in
the neocortex (123). EAAT3 is also found in the Purkinje cell dendrites, as
well as in the other neuron types present, but at low levels (193) (Copyright:
Neurotransporter.org; Reproduced with permission).
in mice confirmed this conclusion as the glutamate uptake activity
was reduced to 5% compared to wildtype mice (190–193) without
changing the expression of other glutamate transporters, gluta-
mine synthetase (GS), and glutamate GluR1 receptors (194). Fur-
ther, electrophysiological recordings of glutamate transporter cur-
rents from hippocampal astrocytes and from human embryonic
kidney 293 cells expressing human EAAT2 are statistically indis-
tinguishable suggesting that the transporter currents in astrocytes
result from EAAT2 or a functionally identical isoform (155).
EAAT1 (Figures 1 and 2) is the predominant glutamate trans-
porter in the cerebellum (162, 195), the inner ear (196, 197), the
circumventricular organs (198), and in the retina [Ref. (199–204);
for review, see Ref. (205)].
EAAT2 and EAAT1 are the only glutamate transporters
expressed in brain astrocytes as both EAAT3 (193, 206) and EAAT4
(123, 207, 208) are neuronal. Within the CNS, EAAT5 is preferen-
tially expressed in the retina and expression in the brain is very low.
It is interesting to note that also in insects (at least in the cabbage
looper Trichoplusia ni) glial cells have high densities of glutamate
transporters in their plasma membranes (209, 210).
EAAT3 is a neuronal transporter as originally suggested (62,
183, 211) and is not expressed in glial cells (193, 206). It appears
to be expressed in the majority if not all neurons throughout the
CNS, but is selectively targeted to somata and dendrites avoiding
axon terminals (193, 206). Within the CNS, it is found in the high-
est concentration in the hippocampus, but the total tissue content
in young adult rat brains is about 100 times lower than that of
EAAT2 (193).
EAAT4 is predominantly found in the cerebellar Purkinje cells
(66, 123) where it is targeted to the dendrites, the spines in
FIGURE 3 | Peroxidase labeling of GAT3 (A) and GAT1 (B) in the
cerebellum [as described Ref. (175, 276)]. GAT1 (slc6a1) and GAT3
(slc6a11) are the two GABA transporters that are functionally relevant for
brain function, and these transporters are not expressed in the liver and
kidney (181). GAT1 is mostly localized in axonal terminals in molecular layer
(m) and GAT3 is in astroglial processes in granular layer (g). Note very high
levels of GAT1 in basket cell terminals around the Purkinje cells (P). Scale
bar: 20µm (Copyright: Neurotransporter.org; Reproduced with permission).
particular (123), but there is also some EAAT4 in a subset of
forebrain neurons (123, 207, 208).
Outside the CNS, EAAT2 is primarily expressed in glandular
tissue, including mammary gland, lacrimal gland, and ducts and
acini in salivary glands (212) and by perivenous hepatocytes (212,
213). It is not present in the heart (214). Thus, the main roles of
EAAT2 are in the brain [for review, see Ref. (3, 15, 16)]. EAAT1 is
found in several non-neuronal tissues (212) including, the heart,
fat cells, and taste buds (212, 214, 215), but does not appear to be
important in controlling bone growth (216). EAAT3 is present in
the kidney (62, 193). The heart expresses EAAT1, EAAT3, EAAT4,
and EAAT5, but not EAAT2 (214).
NEURONAL EXPRESSION OF THE EAAT2 PROTEIN
EAAT2 mRNA is detected in astrocytes, but is also found in some
neurons: pyramidal cells in CA3 hippocampus and in layer VI
of the parietal neocortex (217–219). In fact, EAAT2 mRNA is
reported in the majority of neurons in the neocortex and in
parts of the olfactory bulb, thalamus, and inferior olive (188).
That neurons have the potential to express EAAT2 protein is
clear. Cultured neurons from hippocampus and cortex can express
EAAT2 protein (220–222). Further, EAAT2 is transiently localized
on growing axons of the mouse spinal cord before establishing
astrocytic expression (223). Finally, in the normal and mature
mammalian retina, EAAT2 protein is not expressed in retinal glial
www.frontiersin.org November 2013 | Volume 4 | Article 165 | 5
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FIGURE 4 | Confocal imaging of GAT2 and BGT1 protein in the
cerebellum [as described Ref. (106, 181)]. (A1–A3) Show double
labeling for GAT2 (red) and the astroglial marker GFAP (green). (B1–B3)
Show double labeling for BGT1 (red) and the endothelial marker CD31
(green). The nuclei were visualized in blue by DAPI. Note that both GAT2
and BGT1 are found at the leptomeninges external to glia limitans. Also
note that there is no co-localization of GAT2 with GFAP, and no
co-localization of BGT1 with endothelial marker. In fact, BGT1 (106, 167)
and GAT2 (181) are hardly expressed in the brain at all, but are highly
expressed in the liver and kidney. Abbreviations: m, molecular layer; g,
granular layer. Scale bar: 20µm (Copyright: Neurotransporter.org;
Reproduced with permission).
cells (neither in the Müller cells nor the astrocytes), but is exclu-
sively expressed in neurons (cone photoreceptors and bipolar cells)
(201, 205, 224–226).
Nevertheless, this was controversial for a long time and remains
to be fully resolved. What is clear is that there is a significant
glutamate uptake into glutamatergic nerve terminals, at least in
the hippocampus CA1 [Ref. (227) for a review, see section 4.2
in Ref. (3)]. Glutamatergic axon terminals in hippocampus CA1
express EAAT2 protein, albeit at low levels (154, 228–231) and
this transporter is responsible for the glutamate uptake activity in
hippocampal terminals because it is absent in EAAT2 knockout
mice and is sensitive to inhibition by dihydrokainate (193, 229).
Because these terminals originate from the CA3 pyramidal cells, it
makes sense that these cells have high levels of EAAT2 mRNA. This
is further confirmed by the recent observation from EAAT2 eGFP
BAC reporter mice (232). There is now consensus up to here, but
at least two questions remain:
(a) Is nerve terminal glutamate uptake functionally relevant? Why
was about half of all d-aspartate taken up by hippocampus
slices found to in axon terminals when terminals only contain
around 10% of the EAAT2 protein (229)? This uptake cannot
simply be disregarded as an in vitro artifact due to a higher
rate of heteroexchange than net uptake (233). Preliminary
data from selective deletion of EAAT2 in axon terminals indi-
cate disturbances in synaptic transmission (234), and thereby
may suggest that EAAT2 in terminals is functionally relevant.
(b) Do CA3 pyramidal neurons represent special cases or is most
of the so called synaptosomal uptake measured in other brain
regions also due to nerve terminal EAAT2?
Data obtained with EAAT2 eGFP BAC reporter mice (232) tend
to favor a “yes” to this question, while in situ hybridization data
argue for a “no” [e.g., Ref. (154, 235)].
LESSONS FROM GABA TRANSPORTER KNOCKOUTS
GAT1-deficient mice were generated as an intermediate in the
construction of the mGAT1-GFP strain (236). As GAT1 is
the major GABA transporter, one might expect that deletion
would lead to increased extracellular GABA levels and inhibition.
Reduced aggression (237), hypoalgesia (238), reduced anxiety, and
depression-like behaviors (239) and altered behavioral responses
to ethanol (240) may be largely as expected. However, things are
more complicated. One complicating factor is that the brain still
expresses GAT3 in astrocytes. Another point is that GAT1 is mostly
in terminals where it recycles GABA, and GAT1 deletion leads to
decreased quantal GABA release, and a differential tonic activa-
tion of GABA(A) versus GABA(B) receptors in the hippocampus
(241), as well as to tremor, ataxia, nervousness, and increased
GABA-induced tonic conductance in cerebellum (242). This phe-
notype resembles adverse effects of tiagabine treatment. Tiagabine
is highly selective for GAT1 (115). It has effects on seizure control
and behavior, but side effects are fatigue, dizziness, psychomotor
slowing, ataxia, gastrointestinal upset, weight change, and insom-
nia (243). In human populations there is genetic variation within
the GAT1 gene (slc6a1) and these may be associated with anxiety
disorders with panic symptoms (244).
Deletion of BGT1 in mice does not affect seizure thresholds
(corneal kindling; minimal clonic and tonic extension threshold
test; 6 Hz seizure threshold test; pentamethylenetetrazole-induced
seizure) of adult mice (167) in agreement with the fact that it is
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predominantly expressed in the liver and at lower levels in the kid-
neys and at the brain surface (106). Deletion of GAT2 in mice leads
to changes in liver and brain taurine contents (181), but also does
not appear to give any symptoms from the nervous system under
non-challenging rearing conditions (181). Obviously, it would be
interesting to study the consequences of the deletion of GAT3.
These studies are under way as GAT3 knockout mice have been
made by Yun Zhou, C. Guo, and Niels Christian Danbolt.
LESSONS FROM GLUTAMATE TRANSPORTER KNOCKOUTS
The possibility of connections between malfunctioning glutamate
transporters and disease has got considerable attention [e.g., for
review, see Ref. (3, 74, 245, 246)]. Observations of the EAAT2
knockout mice illustrate why (190, 191). Deletion of the EAAT2
gene causes, in agreement with biochemical data (59, 129), a reduc-
tion in glutamate uptake activity by about 95% (155, 190, 192,
193) and increased extracellular glutamate levels (247, 248). This
has dramatic consequences as they grow up. Mice deficient in
EAAT2 are not conspicuous at birth, but at 3 weeks of age they can
readily be identified because they are hyperactive, epileptic, and
smaller than their wildtype littermates. About half of the mice die
from spontaneous seizures before they reach 4 weeks of age (190).
The gradual increase in severity parallels the postnatal increase in
EAAT2 expression in wildtype animals (249, 250), and in produc-
tion of transmitter glutamate via the glutamate-glutamine cycle
[reviewed by Ref. (251)]. The heterozygote EAAT2 knockout mice
(±) exhibit a 59% decrease in EAAT2 protein levels in the brain,
but do not show any apparent morphological brain abnormalities
and have a similar life-span as their wildtype littermates (192).
There are only moderate behavioral alterations (mild sensorimo-
tor impairment, hyperlocomotion lower anxiety, better learning
of cue-based fear conditioning), but worse context-based fear
conditioning (192). However, the histological outcomes follow-
ing traumatic spinal cord injury is worse in agreement with the
notion that they are less protected (252). No humans have been
identified at being EAAT2 deficient, but there are some reports
on mutations. One patient with amyotrophic lateral sclerosis was
found to harbor a mutated EAAT2 (253, 254) and associations of
mutations with alcoholism (255), schizophrenia (256), smoking
behavior (257), essential tremor (258), and bipolar disorder (259)
have been reported, but it is too early to make firm conclusions.
Mice lacking EAAT1 (260) develop normally, but show symp-
toms of insufficient glutamate uptake in regions where EAAT1
is the major glutamate transporter. Thus, cerebellar function is
affected resulting in reduced motor coordination and increased
susceptibility to cerebellar injury (260), disturbance of the inner
ear with exacerbation of noise-induced hearing loss (261) and
disturbed retinal function (262). The EAAT1 knockout mice also
display poor nesting behavior; abnormal sociability, reduced alco-
hol intake, and reward (260, 263–265). Lack of GLAST does not
lead to spontaneous seizures like those seen in connection with
EAAT2-deficiency, but when seizures are initiated, then lack of
GLAST increases seizure duration and severity (266). In humans,
mutations in EAAT1 are associated with episodic ataxia (246,
267, 268).
Mice lacking EAAT3 (269) develop dicarboxylic aminoaciduria,
and possibly a somewhat reduced spontaneous locomotor activity
(open field). They do not show signs of neurodegeneration
at young age and do not have epilepsy (269–271), but may
age prematurely (270). Humans lacking EAAT3 develop dicar-
boxylic aminoaciduria as expected from the mice data (272).
Further, human EAAT3 polymorphisms have been reported to
be associated with obsessive–compulsive disorders (273, 274).
CONCLUDING REMARKS
The various GABA and glutamate transporters have select expres-
sion patterns and distributions. The literature, however, has
become confusing in part due to poorly controlled immuno-
cytochemistry. A major reason for the latter is the reliance on
the pre-absorption test which easily gives a misleading impres-
sion of specificity [for discussion, see Ref. (149)]. Post-mortem
proteolysis has also contributed to confusion concerning distri-
butions in humans (152). To sum up (for references, see above):
GAT3 and EAAT1 (GLAST) are both selectively expressed in astro-
cytes throughout the CNS, while EAAT3 (EAAC1) and EAAT4 are
selective for neurons. EAAT3 is expressed by most if not all neu-
rons, while EAAT4 is only expressed in subpopulations. GAT1
and EAAT2 (GLT-1) are both in terminals (GABAergic and gluta-
matergic, respectively) and in astrocytes, but differ in that EAAT2
is predominantly in astrocytes throughout the CNS except in the
retina, while GAT1 is only predominantly astrocytic at some loca-
tions (e.g., thalamus). EAAT2 is the only one of these transporters
that is required for survival under non-challenging conditions.
GAT2 and BGT1 are both expressed in the leptomeninges, but
are not significantly expressed not around synapses (in neuropil).
GAT2 is also found in some blood vessels. All these transporters
are highly conserved between mammals, and they play different
roles, some of which remains to be fully understood.
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